Eisai Exits Dermatology Through Roivant Deal
This article was originally published in PharmAsia News
Executive Summary
Eisai has followed in the footsteps of Japanese peer Astellas by divesting assets in the dermatology area, this time through a deal with Roivant for a clinical stage atopic dermatitis therapy that it sees as no longer fitting into its strategic priorities.
You may also be interested in...
Kyowa Kirin’s Parkinson’s Successor Shows Phase IIb Promise
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Need a specific report? 1000+ reports available
Buy Reports